Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Epigenetic regulation of melanoma phenotypic plasticity and therapeutic resistance [ChIP-seq]

ABSTRACT: Melanoma progression and treatment failure are driven in part by the ability of tumor cells to undergo dynamic phenotypic state transitions. Here, we identify the SAGA chromatin-modifying complex as a critical epigenetic regulator that constrains melanoma phenotypic plasticity and preserves therapeutic vulnerability. Loss of SAGA-dependent epigenetic regulation disrupts lineage-associated chromatin states, leading to widespread transcriptional reprogramming and enhanced cellular adaptability. As a consequence, SAGA-deficient melanoma cells exhibit increased phenotypic heterogeneity and acquire resistance to targeted therapy. Mechanistically, SAGA loss impairs histone acetylation–dependent control of gene expression programs linked to differentiation and stress responses, enabling the emergence of drug-tolerant cell states. Together, these findings establish SAGA as an epigenetic safeguard against melanoma cell-state plasticity and reveal how disruption of chromatin regulatory complexes promotes therapeutic resistance.

ORGANISM(S): Homo sapiens

PROVIDER: GSE316110 | GEO | 2026/04/29

REPOSITORIES: GEO

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
		Other

Items per page:

1 - 1 of 1

Similar Datasets

Epigenetic regulation of melanoma phenotypic plasticity and therapeutic resistance

Project description:Melanoma progression and treatment failure are driven in part by the ability of tumor cells to undergo dynamic phenotypic state transitions. Here, we identify the SAGA chromatin-modifying complex as a critical epigenetic regulator that constrains melanoma phenotypic plasticity and preserves therapeutic vulnerability. Loss of SAGA-dependent epigenetic regulation disrupts lineage-associated chromatin states, leading to widespread transcriptional reprogramming and enhanced cellular adaptability. As a consequence, SAGA-deficient melanoma cells exhibit increased phenotypic heterogeneity and acquire resistance to targeted therapy. Mechanistically, SAGA loss impairs histone acetylation–dependent control of gene expression programs linked to differentiation and stress responses, enabling the emergence of drug-tolerant cell states. Together, these findings establish SAGA as an epigenetic safeguard against melanoma cell-state plasticity and reveal how disruption of chromatin regulatory complexes promotes therapeutic resistance.

2026-04-29 | GSE315960 | GEO

Epigenetic regulation of melanoma phenotypic plasticity and therapeutic resistance [CRISPR Screen]

2026-04-29 | GSE316133 | GEO

Epigenetic regulation of melanoma phenotypic plasticity and therapeutic resistance [ATAC-seq]

2026-04-29 | GSE316132 | GEO

Epigenomic profiling of H3K9me3 and H3K27ac across melanoma cell lines with different mutational backgrounds

Project description:Melanoma is a genetically and phenotypically heterogeneous cancer, and changes in chromatin state have been implicated in melanoma progression, phenotypic plasticity, and tumor behavior. To investigate the epigenetic landscape associated with melanoma aggressiveness and mutational background, we performed ChIP-seq for the active chromatin mark H3K27ac and the repressive chromatin mark H3K9me3 in five human melanoma cell lines: SK-Mel-19, SK-Mel-29, SK-Mel-103, UACC-62, and UACC-257. These cell lines represent melanomas with different degrees of aggressiveness and distinct mutation profiles. Our analysis revealed differential patterns of H3K27ac across the cell lines, suggesting that enhancer-associated chromatin states are linked to mutation-dependent transcriptional regulation in melanoma.

2026-05-01 | GSE329231 | GEO

Epigenetic regulation of melanoma phenotypic plasticity and therapeutic resistance

Project description:Epigenetic regulation of melanoma phenotypic plasticity and therapeutic resistance

| PRJNA1400009 | ENA

Epigenetic regulation of melanoma phenotypic plasticity and therapeutic resistance [ChIP-seq]

Project description:Epigenetic regulation of melanoma phenotypic plasticity and therapeutic resistance [ChIP-seq]

| PRJNA1400616 | ENA

Epigenetic regulation of melanoma phenotypic plasticity and therapeutic resistance [CRISPR Screen]

Project description:Epigenetic regulation of melanoma phenotypic plasticity and therapeutic resistance [CRISPR Screen]

| PRJNA1401677 | ENA

Epigenetic regulation of melanoma phenotypic plasticity and therapeutic resistance [ATAC-seq]

Project description:Epigenetic regulation of melanoma phenotypic plasticity and therapeutic resistance [ATAC-seq]

| PRJNA1401678 | ENA

HDAC8-mediated inhibition of EP300 drives a transcriptional state that increases melanoma brain metastasis

Project description:Melanomas are heterogeneous and adopt multiple transcriptional states that can confer an invasive phenotype and resistance to therapy. Little is known about the epigenetic drivers of these cell states, limiting our ability to regulate melanoma heterogeneity and tumor progression. Here we identify stress-induced HDAC8 activity as the driver of a transcriptional state that increased the formation of melanoma brain metastases (MBM). Exposure of melanocytes and melanoma cells to multiple different stresses led to HDAC8 activation, a switch to a gene expression signature associated with a neural crest-stem cell like state (NCSC) and the adoption of an amoeboid, invasive phenotype. This cell state enhanced the survival of melanoma cells under shear stress conditions and increased the formation of metastases in the brain. ATAC-Seq and ChIP-Seq analysis showed HDAC8 to alter chromatin structure by increasing H3K27ac and accessibility at c-Jun binding sites without changing global histone acetylation. The increased accessibility of Jun binding sites was paralleled by decreased H3K27ac and accessibility at MITF binding sites and loss of melanoma-lineage gene expression. Mass spectrometry-based acetylomics demonstrated that HDAC8 deacetylated the histone acetyltransferase (HAT) EP300 leading to its enzymatic inactivation. This, in turn, led to an increased binding of EP300 to Jun-transcriptional sites and decreased binding to MITF-transcriptional sites. Increased expression of EP300 decreased invasion and increased the sensitivity of melanoma cells to multiple stresses while inhibition of EP300 function increased invasion, resistance to stress and the development of MBM. We identified HDAC8 as a novel mediator of transcriptional co-factor inactivation and chromatin accessibility that increases MBM development.

2023-09-26 | PXD044471 | Pride

RNA-seq profiling of SOX10 overexpression in TADA2B KO A375 melanoma cells

Project description:SOX10 is a key regulator of melanoma lineage identity, and TADA2B is a component of the SAGA histone acetyltransferase complex. To investigate the transcriptional interplay between SOX10 and TADA2B, bulk RNA sequencing (RNA-seq) was performed in control and TADA2B KO A375 melanoma cells with and without SOX10 overexpression. This dataset enables comparative analysis of gene expression programs associated with SOX10 activation, loss of TADA2B, and their combined perturbation, providing a resource to examine how SAGA-dependent epigenetic regulation influences melanoma transcriptional states.

2026-04-29 | GSE319449 | GEO

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data